Ken Griffin Ascendis Pharma A/S Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Citadel Advisors LLC holds 15,400 shares of ASND stock, worth $2.09 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,400
Previous 23,400
34.19%
Holding current value
$2.09 Million
Previous $2.95 Million
21.0%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding ASND
# of Institutions
211Shares Held
46.5MCall Options Held
310KPut Options Held
306K-
Artisan Partners Limited Partnership Milwaukee, WI5.67MShares$770 Million1.32% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.08MShares$553 Million3.29% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.97MShares$539 Million7.23% of portfolio
-
Janus Henderson Group PLC London, X03.77MShares$512 Million0.32% of portfolio
-
Wellington Management Group LLP Boston, MA2.75MShares$373 Million0.08% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.58B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...